5 Key Takeaways

• 1

  Ligneous conjunctivitis is the primary manifestation of plasminogen deficiency type 1 (PLGD-1), affecting 81% of patients with ocular symptoms.

• 2

  PLGD-1 leads to painful ligneous lesions on mucosal membranes, which can cause significant organ dysfunction and vision impairment if untreated.

• 3

  RYPLAZIM, a newly FDA-approved treatment, has shown effectiveness in resolving lesions associated with PLGD-1, with 78% of external lesions resolved by week 48.

• 4

  Diagnosis of PLGD-1 can be challenging due to its varied symptoms, necessitating communication among healthcare providers for effective management.

• 5

  The case study highlights the importance of genetic evaluation and plasminogen activity testing in patients with recurrent conjunctivitis unresponsive to standard treatments.